ClinicalTrials.gg
RecruitingNCT06273072Updated Oct 16, 2026

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

A Phase 2 interventional study of Metformin hydrochloride extended-release tablets and Visually identical placebo Metformin hydrochloride extended-release tablets in Asthma, Asthma Chronic and Overweight and Obesity, sponsored by Johns Hopkins University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 16, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Asthma by Johns Hopkins University — 3 open to participants now, 4 under way, none of them phase 3. Asthma · Johns Hopkins University.

Planned enrollment
17th of 30
100 · median 118
Started
2024
the only one that year
Phase 2
6 of 33
1 open now
Registered
33rd of 33
by date

Among the 33 studies in Asthma by Johns Hopkins University, this one is the 17th largest by planned enrollment of the 30 interventional ones that give a count, is the only one that started in 2024, is one of 6 in phase 2, and was the 33rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 33 studies in Asthma by Johns Hopkins University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Asthma by Johns Hopkins University, or all of them as a file.
02

Study summary

This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.

Read the detailed description

This is a randomized, placebo-controlled, parallel-arm pilot clinical trial. Adult participants who are overweight or obese and have not well-controlled asthma despite use of an inhaled corticosteroid will be randomized to metformin, an FDA-approved medication for the treatment of type 2 diabetes mellitus, or to placebo, to be taken daily for a total duration of six months. Recruitment will occur at two sites in the United States.

Randomized participants will have regular telemedicine visits to assess side effects and adherence. Additionally, participants will have a measurement of asthma outcomes at randomization and at 3 and 6 months after randomization.

The purpose of this study is to determine feasibility to inform a future multi-center clinical trial of metformin in this population.

03

Conditions studied

  • Asthma
  • Asthma Chronic
  • Overweight and Obesity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician-diagnosed asthma on maintenance therapy
  • Not well-controlled asthma (ACT score \<20, or at least one asthma exacerbation requiring in the prior 12 months)
  • Overweight or obesity: ≥25kg/m2
  • Adult: Age ≥18

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant, expect to become pregnant in the next 6 months or are currently breastfeeding
  • Major cardiovascular disease: heart failure, heart attack or stroke within the last 6 months
  • Other chronic lung disease, inclusive of , bronchiectasis, interstitial lung disease, pulmonary fibrosis
  • Active smoking or former smoker with ≥20 pack-year smoking history
  • Chronic kidney disease: estimated ≤60 mL/min/1.73 m2
  • Heavy alcohol use: in a typical week, 8 or more drinks for a woman or 15 or more drinks for a man
  • Liver disease: elevation in (AST) or alanine aminotransferase (ALT) > 2x the or prior diagnosis of liver disease
  • Anemia: \< 13 g/dl in males and hemoglobin \< 11 g/dl in females
  • Taking Glucagon Like Peptide 1(GLP-1) medications for weight loss
  • Diabetes ( ≥ 6.5% or taking metformin or other medications used to treat diabetes)
  • Participation in any other clinical trial (observational studies are permitted)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Metformin hydrochloride extended-release tablets

    Metformin hydrochloride extended-release tablets 2000 mg once daily

    Drug: Metformin hydrochloride extended-release tablets

  • Placebo comparator
    Visually identical placebo tablets

    Placebo tablet once daily

    Drug: Visually identical placebo Metformin hydrochloride extended-release tablets

Interventions

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    titrated to 2000 mg once daily

  • DrugVisually identical placebo Metformin hydrochloride extended-release tablets

    placebo

06

What researchers measure

Primary outcomes

  1. Number of completed telemedicine visits

    Number of participants completing at least 3 out of the 4 monitoring telemedicine visits

    Time frame: Baseline to week 24

  2. Adherence to study drug

    Adherence will be measured by pill count

    Time frame: Baseline to week 24

  3. Retention rate

    Investigators will collect data on the number of subjects screened, randomized, and complete the final in-person visit

    Time frame: Baseline to week 24

Secondary outcomes

  1. Asthma control as assessed by the Asthma Control Test (ACT) score

    Difference in Asthma Control Test (ACT) score at week 24; range is from 5-25 with higher being better asthma control

    Time frame: Baseline to week 24

  2. Change in Asthma exacerbations rate

    Change in (annualized) asthma exacerbations rate at week 24

    Time frame: Baseline to week 24

  3. Pre-bronchodilator lung function

    Difference in volume of air exhaled in the first second during spirometry (FEV1) at week 24

    Time frame: Baseline to week 24

  4. Fractional exhaled nitric oxide (FeNO)

    Difference in FeNO between baseline and week 24

    Time frame: Baseline to week 24

  5. Airways hyperresponsiveness

    Difference in cumulative dose of mannitol required to precipitate a significant decrement in FEV1 between baseline at week 24

    Time frame: Baseline to week 24

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 62 non-industry phase 2 interventional studies under Asthma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's planned 24 months is below that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2024
First posted
Feb 22, 2024
StartActual
Dec 9, 2024
Primary completionEst.
Dec 31, 2026was Sep 2026
CompletionEst.
Dec 31, 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Dec 31, 2026
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Primary completion Sep 30, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06273072
Responsible party
Sponsor
First posted
Feb 22, 2024
Start date
Dec 9, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Rachelle Koehl, M.S.
Contact
rkoehl1@jhmi.edu
410-955-1530
Meredith C McCormack, M.D., M.H.S.
Contact
mmccor16@jhmi.edu
410-550-6205
Meredith C McCormack, M.D., M.H.S.
principal investigator · Johns Hopkins University
Tianshi D Wu, M.D., M.H.S.
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion